Anti-Tumor Immunity Elicited by Peptide Complex-Alpha-Fetoprotein and Glycoprotein 96

Abstract:

Purposes: To construct a recombinant vaccine alpha-fetoprotein (AFP)-glycoprotein (gp96) complex, and study its ability to induce specific CTL response and its protective effect against AFP-producing tumor. Material/Methods: A recombinant vaccine was constructed by conjugating mouse alpha-fetoprotein to glycoprotein 96. By way of intracutaneous injection, mice were primed and boosted with recombinant vaccine mAFP/gp96, whereas single mAFP or gp96 injection as controls. The ELISPOT and ELISA were used to measure the frequency of cells producing the cytokine IFN-gama in splenocytes and the level of anti-AFP antibody of serum from immunized mice respectively. In vivo tumor challenge was carried out to assess the immune effect of the recombinant vaccine. Results: By recombinant mAFP/gp96 vaccine immunization, the results of ELISPOT and ELISA showed that the number of splenic cells producing IFN-gama and the level of anti-AFP antibody of serum were significantly higher in mAFP/gp96 group than those in mAFP and gp96 groups (122.50±9.30 IFN-gama spots/10⁶ cells vs 46.40±10.32 IFN-gama spots/10⁶ cells, 12.14±7.33 IFN-gama spots/10⁶ cells, P<0.01; 164.52±11.22 µg/mL vs 56.32±8.23 µg/mL, 7.56±3.47 µg/mL, P< 0.01). The tumor volume in mAFP/gp96 group was significantly smaller than that in mAFP and gp96 groups (32.46±6.35 mm³ vs 384.16±11.43 mm³, 832.54±12.72 mm³, P< 0.01). Conclusions: The study further confirmed the function of glycoprotein 96s immune adjuvant. Sequential immunization with recombinant mAFP/gp96 vaccine could generate effective antitumor immunity on AFP-producing tumor. The recombined mAFP/gp96 vaccine may be suitable for serving as an immunotherapy for hepatocellular carcinoma.

• Periodical: Applied Mechanics and Materials (Volumes 195-196)
• Pages: 397-401
• DOI: https://doi.org/10.4028/www.scientific.net/AMM.195-196.397
• Online since: August 2012
• Authors: Xiao Ping Wang, Huan Ping Lin, Qiao Xia Wang
• Keywords: Alpha-Fetoprotein (AFP), Glycoprotein96 (gp96), Immunity, Recombinant Vaccine

References

[1] D.F. Schafer, and M.F. Sorrell, Hepatocellular carcinoma, Lancet, vol. 353 (9160), pp.1253-1257, (1993).

DOI: 10.1016/s0140-6736(98)09148-x

[2] Z.Y. Tang, Hepatocellular carcinoma-cause, treatment and metastasis, World J. Gastroenterol., vol. 7 (4), pp.445-454, (2001).

[3] P. Hanke, C. Rabe, M. Serwe, S. Bohm, C. Pagenstecher, T. Sauerbruch, and W.H. Caselmann, Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein, Scand. J. Gastroenterol., vol. 37 (8), pp.949-955, (2002).

DOI: 10.1080/003655202760230928

[4] A. Saeki, K. Nakao, Y. Nagayama, K. Yanagi, K. Matsumoto, T. Hayashi, et al. Diverse efficacy of vaccination therapy using the alpha-fetoprotein gene against mouse hepatocellular carcinoma, Int. J. Mol. Med., vol. 13 (1), pp.111-116, (2004).

DOI: 10.3892/ijmm.13.1.111

[5] C.F. Grimm, D. Ortmann, L. Mohr, S. Michalak, T.U. Krohne, S. Meckel, et al. Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice, Gastroenterology, vol. 119 (4), pp.1104-1112, (2000).

DOI: 10.1053/gast.2000.18157

[6] P. Hanke, M. Serwe, F. Dombrowski, T. Sauerbruch, and W.H. Caselmann, DNA vaccination with AFP-encoding plasmid DNA prevents growth of subcutaneous AFP-expressing tumors and does not interfere with liver regeneration in mice, Cancer Gene Ther., vol. 9 (4), pp.346-355, (2002).

DOI: 10.1038/sj.cgt.7700445

[7] D.G. Casey, J. Lysaght, T. James, A. Bateman, A.A. Melcher, and S.M. Todryk, Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine., Immunology, vol. 110 (1), pp.105-111, (2003).

DOI: 10.1046/j.1365-2567.2003.01726.x

[8] X.F. Huang, W. Ren, L. Rollins, P. Pittman, M. Shah, L. Shen, et al. A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine, Cancer Res., vol. 63 (21), pp.7321-7329, (2003).

[9] T.H. Schreiber, V.V. Deyev, J.D. Rosenblatt, and E.R. Podack, Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination, Cancer Res., vol. 69(5), pp.2026-2033, (2009).

DOI: 10.1158/0008-5472.can-08-3706

[10] L.H. Butterfield, A. Koh, W. Meng, C.M. Vollmer, A. Ribas, V. Dissette, et al. Generation of human T-cell responses to an HLA-A2. 1-restricted peptide epitope derived from alpha-fetoprotein, Cancer Res., vol. 59 (13), pp.3134-3142, (1999).

DOI: 10.4049/jimmunol.166.8.5300

[11] W.S. Meng, L.H. Butterfield, A. Ribas, J.B. Heller, V.B. Dissette, J.A. Glaspy, et al. Fine specificity analysis of an HLA-A2. 1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein, Mol. Immunol., vol. 37 (16), pp.943-950, (2000).

DOI: 10.1016/s0161-5890(01)00017-7

[12] J. Banchereau, and R.M. Steinman, Dendritic cells and the control of immunity, Nature, vol. 392 (6673), pp.245-252, (1998).

DOI: 10.1038/32588

[13] C.M. Jr Vollmer, F.C. Eilber, L.H. Butterfield, A. Ribas, V.B. Dissette, A. Koh, et al. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma, Cancer Res., vol. 59 (13), pp.3064-3067, (1999).

[14] A. Murshid, J. Gong, and S.K. Calderwood, Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation, Expert Rev. Vaccines, vol. 7(7), pp.1019-1030, (2008).

DOI: 10.1586/14760584.7.7.1019

[15] X.P. Wang, G.Z. Liu, A.L. Song, H.Y. Li, and Y. Liu, Antitumor immunityinduced by DNA vaccine encoding alpha-fetoprotein/heat shock protein 70, World J. Gastroenterol., vol. 10 (21), pp.3197-3200, (2004).

DOI: 10.3748/wjg.v10.i21.3197

[16] N. Pakravan, L. Langroudi, M. Hajimoradi, and Z.M. Hassan, Co-administration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model, Cell Stress Chaperones, vol. 15(6), pp.977-984, (2010).

DOI: 10.1007/s12192-010-0208-8

[17] N. Strbo and E.R. Podack, Secreted heat shock protein gp96-Ig: an innovative vaccine approach, Am. J. Reprod. Immunol., vol. 59(5), pp.407-416, (2008).

DOI: 10.1111/j.1600-0897.2008.00594.x